智通财经APP讯，乐普生物-B(02157)发布截至2024年12月31日止年度业绩，该集团期内取得收入3.68亿元(人民币，下同)，同比增加63.21%;公司拥有人应占亏损4.11亿元，同比扩大1761.77%;每股基本亏损0.24元。
公告称，收入增加由于(i)销售普佑恒® (普特利单抗注射液)的收入3亿元，几乎为2023年(1.01亿元)的3倍;(ii) CMG901里程碑付款及所提供的技术转让服务的对外授权收入2200万元(2023年：1.24亿元);及(iii)提供CDMO服务4550万元(2023年：0)。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.